Clinical Trials
32 trialsSacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
National Institutes of Health Clinical Center (CC)
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Memorial Sloan Kettering Cancer Center
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
University of California, Irvine
TRAIN-UC-01
Sun Yat-sen University
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Seagen Inc.
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
SHIELD
China Medical University, China
IMPROEV
Fox Chase Cancer Center
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
SOGUG-NEOWIN
Spanish Oncology Genito-Urinary Group
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Theralase® Technologies Inc.
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
TALASUR
Centre Francois Baclesse
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
University of Florida
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
GRAPE
Nagoya University
NEPTUNE
University of Michigan Rogel Cancer Center
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd.
A Phase 2 Clinical Study of ABSK061 and ABSK043
Abbisko Therapeutics Co, Ltd
ICONIC
CNAO National Center of Oncological Hadrontherapy
CHASIT
Erasmus Medical Center
iNDUCT
Centre Hospitalier Universitaire de Nīmes
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University